Clinical trials: Hematology
Hematology, Diffused Large B Cell Lymphoma
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231.
- Trial name
- DOMAIN (NCT07065344)
- Where
- 21 sites in Egypt, Iraq and 8 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Hematology, Hematologic Test
Analytical and Clinical Performance Testing Plan
Clinical and analytical tests will be performed based on risk assessment and system specifications to verify that the performance of the investigational device is in accordance with its specifications.
- Trial name
- NCT03595501
- Testing
- Hematology Analyzer - OLO, Hematology Analyzer - Predicate
- Where
- United States
- Volunteers
- 679 people, healthy volunteers welcome
- Sponsor
- Sight Diagnostics
Hematology
Performance Evaluation Study
This study aims to establish OLO's performance accuracy of CBC results for finger prick samples across the OLO reportable range, and particularly around relevant medical decision points
- Trial name
- NCT04618848
- Testing
- Fingerstick blood draw
- Volunteers
- 50 people
- Sponsor
- Sight Diagnostics
Hematology, MDS
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
This is an open label extension study of romiplostim for treatment of thrombocytopenia (platelet count ≤ 50 x 10^9/L) in MDS subjects.
- Conditions
- Hematology, MDS, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00472290
- Testing
- Romiplostim (formerly AMG 531)
- Volunteers
- 72 people
- Sponsor
- Amgen
Cancer, Chronic Lymphocytic Leukemia
AMG 319 Lymphoid Malignancy FIH
This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies
- Trial name
- NCT01300026
- Testing
- AMG 319
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amgen
Hematology
Naproxen Sodium/ASA Platelet Study
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
- Trial name
- Kontakt (NCT02229461)
- Testing
- Naproxen Sodium (Aleve, BAY117031), Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bayer
Lymphoma, Hodgkin's Lymphoma
Pegfilgrastim PBPC Mobilization Study
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize…
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology
- Trial name
- NCT00066092
- Testing
- pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
- Volunteers
- 41 people
- Sponsor
- Amgen